Third Harmonic Bio, Inc. (THRD), a clinical-stage biopharmaceutical company, on Tuesday announced promising results from its Phase 1 clinical trial of THB335, a potent and selective oral small molecule inhibitor of KIT, for chronic spontaneous urticaria or CSU.
The study, which included single and multiple ascending doses or SAD/MAD in healthy volunteers, demonstrated that THB335 was well-tolerated with dose-dependent reductions in serum tryptase, a biomarker of mast cell activation.
The Phase 1 results support the progression of THB335 into Phase 2 clinical trials for CSU, with reductions in tryptase levels believed to provide clinical benefit.
The compound also showed a half-life of approximately 40 hours, allowing for once-daily dosing.
Third Harmonic Bio is initiating a strategic review process to maximize shareholder value, considering potential strategic transactions and business combinations.
The company plans to begin its Phase 2 trial of THB335 in CSU by mid-2025.
Cash position:
As of December 31, 2024, the Company had approximately $285 million in cash and cash equivalents (unaudited).
The Company estimates it will have cash and cash equivalents in a range of approximately $262 million to $267 million on June 30, 2025.
THRD closed Monday's (Feb.10 2025) trading at $4.65 down 4.12%. In premarket trading Tuesday, the stock is down by 27.98% at $3.34.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.